NCT04940546View on ClinicalTrials.gov

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2025

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Sintilimab

Mode of administration: Intravenously

DRUG

Oxaliplatin

Mode of administration: Intravenously

DRUG

Capecitabine

Mode of administration: Orally

DRUG

Bevacizumab

Mode of administration: Intravenously

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER